BR102017010401A2 - anticorpo monoclonal, fragmento de ligação ao antígeno, hibridoma, composição farmacêutica, e, métodos para preparação de um hibridoma e de um anticorpo monoclonal - Google Patents
anticorpo monoclonal, fragmento de ligação ao antígeno, hibridoma, composição farmacêutica, e, métodos para preparação de um hibridoma e de um anticorpo monoclonal Download PDFInfo
- Publication number
- BR102017010401A2 BR102017010401A2 BR102017010401A BR102017010401A BR102017010401A2 BR 102017010401 A2 BR102017010401 A2 BR 102017010401A2 BR 102017010401 A BR102017010401 A BR 102017010401A BR 102017010401 A BR102017010401 A BR 102017010401A BR 102017010401 A2 BR102017010401 A2 BR 102017010401A2
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- hybridoma
- antigen
- binding fragment
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
anticorpo monoclonal, fragmento de ligação ao antígeno, hibridoma, composição farmacêutica, e, métodos para preparação de um hibridoma e de um anticorpo monoclonal. a presente invenção se refere a um anticorpo monoclonal que inibe funções imunossupressoras de patógenos, fragmento de ligação ao antígeno do mesmo, e hibridomas que produzem tal anticorpo. o anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo se liga a um peptídeo consistindo em uma sequência de aminoácidos representada por mekvgkdgvitve (seq id no: 1). a presente invenção também descreve uso do anticorpo monoclonal inventado ou fragmento de ligação ao antígeno do mesmo, e método de preparação para tais hibridomas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/165,723 US10577409B2 (en) | 2016-05-26 | 2016-05-26 | Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR102017010401A2 true BR102017010401A2 (pt) | 2020-04-28 |
Family
ID=60421016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR102017010401A BR102017010401A2 (pt) | 2016-05-26 | 2017-05-18 | anticorpo monoclonal, fragmento de ligação ao antígeno, hibridoma, composição farmacêutica, e, métodos para preparação de um hibridoma e de um anticorpo monoclonal |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10577409B2 (pt) |
| JP (1) | JP6776033B2 (pt) |
| KR (1) | KR102241619B1 (pt) |
| AU (1) | AU2017203225B2 (pt) |
| BR (1) | BR102017010401A2 (pt) |
| CA (1) | CA2967597C (pt) |
| IL (1) | IL251997A0 (pt) |
| MX (1) | MX2017006603A (pt) |
| MY (1) | MY180272A (pt) |
| NZ (1) | NZ731906A (pt) |
| PH (1) | PH12017000140A1 (pt) |
| RU (1) | RU2751918C2 (pt) |
| SG (1) | SG10201704029WA (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220089707A1 (en) * | 2019-02-01 | 2022-03-24 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| AR003125A1 (es) * | 1995-06-01 | 1998-07-08 | Astra Ab | Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la |
| US20040052799A1 (en) * | 1996-11-15 | 2004-03-18 | Astra Aktiebolag | Nucleic acid and amino acid sequences relating to Helicobacter pylori for diagnostics and therapeutics |
| JP4581094B2 (ja) * | 2006-12-07 | 2010-11-17 | 国立大学法人 岡山大学 | 動脈硬化の検査方法 |
-
2016
- 2016-05-26 US US15/165,723 patent/US10577409B2/en active Active
- 2016-07-11 JP JP2016136878A patent/JP6776033B2/ja active Active
-
2017
- 2017-04-24 PH PH12017000140A patent/PH12017000140A1/en unknown
- 2017-04-27 IL IL251997A patent/IL251997A0/en active IP Right Grant
- 2017-04-28 RU RU2017115201A patent/RU2751918C2/ru active
- 2017-04-28 KR KR1020170055184A patent/KR102241619B1/ko active IP Right Grant
- 2017-05-15 AU AU2017203225A patent/AU2017203225B2/en not_active Ceased
- 2017-05-15 NZ NZ731906A patent/NZ731906A/en not_active IP Right Cessation
- 2017-05-17 SG SG10201704029WA patent/SG10201704029WA/en unknown
- 2017-05-17 CA CA2967597A patent/CA2967597C/en active Active
- 2017-05-17 MY MYPI2017701770A patent/MY180272A/en unknown
- 2017-05-18 BR BR102017010401A patent/BR102017010401A2/pt not_active Application Discontinuation
- 2017-05-19 MX MX2017006603A patent/MX2017006603A/es unknown
-
2019
- 2019-09-20 US US16/577,549 patent/US10808025B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017115201A (ru) | 2018-10-29 |
| JP6776033B2 (ja) | 2020-10-28 |
| RU2017115201A3 (pt) | 2020-09-23 |
| US10577409B2 (en) | 2020-03-03 |
| KR102241619B1 (ko) | 2021-04-20 |
| IL251997A0 (en) | 2017-07-31 |
| US20200010534A1 (en) | 2020-01-09 |
| CA2967597A1 (en) | 2017-11-26 |
| PH12017000140B1 (en) | 2018-09-17 |
| PH12017000140A1 (en) | 2018-09-17 |
| AU2017203225A1 (en) | 2017-12-14 |
| US20170342137A1 (en) | 2017-11-30 |
| MX2017006603A (es) | 2018-08-28 |
| AU2017203225B2 (en) | 2018-04-12 |
| NZ731906A (en) | 2018-02-23 |
| MY180272A (en) | 2020-11-26 |
| CA2967597C (en) | 2021-07-06 |
| US10808025B2 (en) | 2020-10-20 |
| KR20170134199A (ko) | 2017-12-06 |
| RU2751918C2 (ru) | 2021-07-20 |
| SG10201704029WA (en) | 2017-12-28 |
| JP2017209100A (ja) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501464A1 (en) | Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier | |
| BR112019003775A2 (pt) | anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos | |
| BR112017009817A2 (pt) | anticorpos anti-il-1beta e métodos de utilização | |
| AR110321A1 (es) | Anticuerpos antitau y métodos de uso | |
| MX2020007888A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PE20240365A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
| PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| EA201790342A1 (ru) | Антитела к trem2 и способы их применения | |
| EA201890302A1 (ru) | Химерные рецепторы антигенов на основе однодоменных антител и способы их применения | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| BR112017014308A2 (pt) | anticorpos biespecíficos contra calicreína plasmática e fator xii | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| BR112017009790A2 (pt) | anticorpos direcionados ao anti-ang2 e métodos de uso | |
| AR114281A1 (es) | Anticuerpos anti-klk5 y métodos de uso | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| WO2018048317A8 (en) | Monoclonal antibodies against hemagglutinin of h5-serotype influenza viruses and their uses, hybridomas producing said antibodies, compositions and diagnostic kits | |
| PH12016501579B1 (en) | Novel anti-presepsin antibody | |
| BR102017010401A2 (pt) | anticorpo monoclonal, fragmento de ligação ao antígeno, hibridoma, composição farmacêutica, e, métodos para preparação de um hibridoma e de um anticorpo monoclonal | |
| PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
| MX2020010092A (es) | Variantes de anticuerpo c-terminales. | |
| BR112022007306A8 (pt) | Anticorpo antagonista, ou um fragmento do mesmo, sequência de ácido nucleico, vetor, célula hospedeira, imunoconjugado e composição farmacêutica | |
| BR112017003138A2 (pt) | anticorpos anti-hepatite c e seus fragmentos de ligação ao antígeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |